Recombinant Human BCMA/TNFRSF17

Description :
FAQ COA 已发表文献 Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNFreceptor superfamily. It is a type III membrane protein containing one extracellular cysteine rich domain.This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. TNFRSF17 can binds to TNFSF13B/BLyS/BAFF and TNFSF13/APRIL,and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo. Product Properties Synonyms TNFRSF17, BCM, CD269 Accession Q02223 GeneID 608 Source E.coli-derived Human BCMA/TNFRSF17, Ala5-Ala54. Molecular Weight Approximately 5.4kDa. AA Sequence AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 98% by SDS-PAGE and HPLC analyses. Biological Activity The ED50as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/mL, corresponding to a specific activity of > 2.5 104IU/mg in the presence of 100 ng/mLhuman APRIL.Fully biologically active when compared to standard. Endotoxin EUper 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered concentrated solution in 30% acetonitrile, 0.1% TFA. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20C. Further dilutions should be made in appropriate buffered solutions.